MedDataX Logo

Tiotropium Bromide in Cystic Fibrosis

NCT ID: NCT01179347

Last Updated: 2013-12-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

464 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To date, there have been no formal clinical studies completed using tiotropium in CF patients. While there is a large body of evidence demonstrating the efficacy and safety of tiotropium in patients with Chronic Obstructive Pulmonary Disease (COPD), relatively little is known about its efficacy and safety in patients with a diagnosis of cystic fibrosis. Therefore, Boehringer Ingelheim proposed to profile the long acting anticholinergic tiotropium and to generate adequate clinical data for use as a bronchodilator in paediatric and adult CF. The phase III trial (205.438) is a part of the approved Paediatric Investigation Plan (PIP) agreed for Spiriva® Respimat® in Cystic Fibrosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tiotropium

2 inhalations once daily delivered with Respimat® inhaler

Group Type EXPERIMENTAL

tiotropium Respimat® inhaler

Intervention Type DRUG

to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.

placebo

2 inhalations once daily delivered with Respimat® inhaler

Group Type PLACEBO_COMPARATOR

Placebo Respimat® inhaler

Intervention Type DRUG

patient to receive placebo matching active drug once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tiotropium Respimat® inhaler

to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.

Intervention Type DRUG

Placebo Respimat® inhaler

patient to receive placebo matching active drug once daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with a documented diagnosis of Cystic Fibrosis (CF) (positive sweat chloride \>=60 mEq/liter, by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations.
2. Male or female patients (children less than 12 years and adolescents \>12 years).
3. Patients \>=5 years of age must be able to perform acceptable spirometric maneuvers, according to the American Thoracic Society (ATS) standards.
4. Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) \>25% of predicted values.
5. Pre-bronchodilator FEV1 at Visit 2 must be within 15% of FEV1 at Visit 1.
6. No evidence of respiratory tract infection and no pulmonary exacerbation requiring use of intravenous/oral/inhaled antibiotics, or oral corticosteroids within 2 weeks of screening.
7. The patient or the patient's legally acceptable representative must be able to give informed consent.
8. Patients who are on a cycling TOBI® regimen must have completed at least 2 cycles every other month TOBI® administration prior to the screening visit.
9. Patients who are on daily inhaled antibiotic use must be stabilized for at least 6 weeks prior to Visit 1 (screening).
10. Patients having previously participated in study 205.339 can also be selected.

Exclusion Criteria

1. Patients with a known hypersensitivity to study drug
2. Patients who have participated in another study with an Investigational drug within one month preceding the screening visit.
3. Patients who are currently participating in another trial. Observational studies are allowed. Permission should be obtained from sponsor of other study.
4. Patients with known relevant substance abuse, including alcohol or drug abuse.
5. Adolescent and adult female patients who are pregnant or lactating, including females who have a positive serum pregnancy test at screening.
6. Female patients of child bearing potential who are not using a medically approved form of contraception.
7. Clinically significant disease or medical condition other than CF or CF-related conditions that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. Patients with diabetes may participate if their disease is under good control prior to screening.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

205.438.01004 Boehringer Ingelheim Investigational Site

Tuscon, Arizona, United States

Site Status

205.438.01011 Boehringer Ingelheim Investigational Site

San Diego, California, United States

Site Status

205.438.01018 Boehringer Ingelheim Investigational Site

Jacksonville, Florida, United States

Site Status

205.438.01008 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

205.438.01014 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

205.438.01021 Boehringer Ingelheim Investigational Site

Orlando, Florida, United States

Site Status

205.438.01007 Boehringer Ingelheim Investigational Site

Indianapolis, Indiana, United States

Site Status

205.438.01006 Boehringer Ingelheim Investigational Site

South Bend, Indiana, United States

Site Status

205.438.01001 Boehringer Ingelheim Investigational Site

Detroit, Michigan, United States

Site Status

205.438.01010 Boehringer Ingelheim Investigational Site

Manchester, New Hampshire, United States

Site Status

205.438.01003 Boehringer Ingelheim Investigational Site

Syracuse, New York, United States

Site Status

205.438.01019 Boehringer Ingelheim Investigational Site

Cleveland, Ohio, United States

Site Status

205.438.01013 Boehringer Ingelheim Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

205.438.01005 Boehringer Ingelheim Investigational Site

Charleston, South Carolina, United States

Site Status

205.438.01012 Boehringer Ingelheim Investigational Site

Milwaukee, Wisconsin, United States

Site Status

205.438.61003 Boehringer Ingelheim Investigational Site

Chermside, Queensland, Australia

Site Status

205.438.61004 Boehringer Ingelheim Investigational Site

Herston, Queensland, Australia

Site Status

205.438.61001 Boehringer Ingelheim Investigational Site

Adelaide, South Australia, Australia

Site Status

205.438.61002 Boehringer Ingelheim Investigational Site

Subiaco, Western Australia, Australia

Site Status

205.438.43001 Boehringer Ingelheim Investigational Site

Innsbruck, , Austria

Site Status

205.438.43002 Boehringer Ingelheim Investigational Site

Salzburg, , Austria

Site Status

205.438.32002 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

205.438.32004 Boehringer Ingelheim Investigational Site

Edegem, , Belgium

Site Status

205.438.32003 Boehringer Ingelheim Investigational Site

Jette, , Belgium

Site Status

205.438.32001 Boehringer Ingelheim Investigational Site

Leuven, , Belgium

Site Status

205.438.02005 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

Site Status

205.438.02007 Boehringer Ingelheim Investigational Site

Vancouver, British Columbia, Canada

Site Status

205.438.02004 Boehringer Ingelheim Investigational Site

Halifax, Nova Scotia, Canada

Site Status

205.438.02003 Boehringer Ingelheim Investigational Site

Hamilton, Ontario, Canada

Site Status

205.438.02006 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

205.438.02001 Boehringer Ingelheim Investigational Site

Sherbrooke, Quebec, Canada

Site Status

205.438.42002 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

205.438.42003 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

205.438.42004 Boehringer Ingelheim Investigational Site

Olomouc, , Czechia

Site Status

205.438.42001 Boehringer Ingelheim Investigational Site

Prague, , Czechia

Site Status

205.438.33010 Boehringer Ingelheim Investigational Site

Angers, , France

Site Status

205.438.33013 Boehringer Ingelheim Investigational Site

Bron, , France

Site Status

205.438.33002 Boehringer Ingelheim Investigational Site

Lille, , France

Site Status

205.438.33015 Boehringer Ingelheim Investigational Site

Lisieux, , France

Site Status

205.438.33003 Boehringer Ingelheim Investigational Site

Montpellier, , France

Site Status

205.438.33005 Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

205.438.33014 Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

205.438.33001 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

205.438.33006 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

205.438.33007 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

205.438.33011 Boehringer Ingelheim Investigational Site

Rennes, , France

Site Status

205.438.33008 Boehringer Ingelheim Investigational Site

Roscoff, , France

Site Status

205.438.33004 Boehringer Ingelheim Investigational Site

Rouen, , France

Site Status

205.438.33009 Boehringer Ingelheim Investigational Site

Vannes, , France

Site Status

205.438.49001 Boehringer Ingelheim Investigational Site

Bochum, , Germany

Site Status

205.438.49002 Boehringer Ingelheim Investigational Site

Frankfurt, , Germany

Site Status

205.438.49012 Boehringer Ingelheim Investigational Site

Frankfurt, , Germany

Site Status

205.438.49011 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

205.438.49006 Boehringer Ingelheim Investigational Site

Gerlingen, , Germany

Site Status

205.438.49007 Boehringer Ingelheim Investigational Site

Giessen, , Germany

Site Status

205.438.49005 Boehringer Ingelheim Investigational Site

Hamburg, , Germany

Site Status

205.438.49003 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

205.438.49008 Boehringer Ingelheim Investigational Site

Tübingen, , Germany

Site Status

205.438.36002 Boehringer Ingelheim Investigational Site

Budapest, , Hungary

Site Status

205.438.36003 Boehringer Ingelheim Investigational Site

Mosdós, , Hungary

Site Status

205.438.36004 Boehringer Ingelheim Investigational Site

Szeged, , Hungary

Site Status

205.438.35301 Boehringer Ingelheim Investigational Site

Dublin, , Ireland

Site Status

205.438.97003 Boehringer Ingelheim Investigational Site

Haifa, , Israel

Site Status

205.438.97001 Boehringer Ingelheim Investigational Site

Jerusalem, , Israel

Site Status

205.438.97002 Boehringer Ingelheim Investigational Site

Petah Tikva, , Israel

Site Status

205.438.97004 Boehringer Ingelheim Investigational Site

Tel Litwinsky, , Israel

Site Status

205.438.39001 Boehringer Ingelheim Investigational Site

Florence, , Italy

Site Status

205.438.39003 Boehringer Ingelheim Investigational Site

Genova, , Italy

Site Status

205.438.39002 Boehringer Ingelheim Investigational Site

Verona, , Italy

Site Status

205.438.48001 Boehringer Ingelheim Investigational Site

Lodz, , Poland

Site Status

205.438.48002 Boehringer Ingelheim Investigational Site

Rabka-Zdrój, , Poland

Site Status

205.438.48003 Boehringer Ingelheim Investigational Site

Warsaw, , Poland

Site Status

205.438.35001 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

205.438.35002 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

205.438.35003 Boehringer Ingelheim Investigational Site

Porto, , Portugal

Site Status

205.438.35004 Boehringer Ingelheim Investigational Site

Porto, , Portugal

Site Status

205.438.07001 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

205.438.07005 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

205.438.07003 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

205.438.07004 Boehringer Ingelheim Investigational Site

Voronezh, , Russia

Site Status

205.438.07002 Boehringer Ingelheim Investigational Site

Yaroslavl, , Russia

Site Status

205.438.42102 Boehringer Ingelheim Investigational Site

Banská Bystrica, , Slovakia

Site Status

205.438.42101 Boehringer Ingelheim Investigational Site

Bratislava, , Slovakia

Site Status

205.438.42103 Boehringer Ingelheim Investigational Site

Košice, , Slovakia

Site Status

205.438.27001 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

205.438.34005 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

205.438.34001 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

205.438.34002 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

205.438.34004 Boehringer Ingelheim Investigational Site

Valencia, , Spain

Site Status

205.438.41003 Boehringer Ingelheim Investigational Site

Basel, , Switzerland

Site Status

205.438.41004 Boehringer Ingelheim Investigational Site

Bern, , Switzerland

Site Status

205.438.41001 Boehringer Ingelheim Investigational Site

Zurich, , Switzerland

Site Status

205.438.41002 Boehringer Ingelheim Investigational Site

Zurich, , Switzerland

Site Status

205.438.44009 Boehringer Ingelheim Investigational Site

Brighton, , United Kingdom

Site Status

205.438.44007 Boehringer Ingelheim Investigational Site

Cambridge, , United Kingdom

Site Status

205.438.44004 Boehringer Ingelheim Investigational Site

Leeds, , United Kingdom

Site Status

205.438.44005 Boehringer Ingelheim Investigational Site

Nottingham, , United Kingdom

Site Status

205.438.44002 Boehringer Ingelheim Investigational Site

Plymouth, , United Kingdom

Site Status

205.438.44003 Boehringer Ingelheim Investigational Site

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Canada Czechia France Germany Hungary Ireland Israel Italy Poland Portugal Russia Slovakia South Africa Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Ratjen F, Koker P, Geller DE, Langellier-Cocteaux B, Le Maulf F, Kattenbeck S, Moroni-Zentgraf P, Elborn JS; Tiotropium Cystic Fibrosis Study Group. Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. J Cyst Fibros. 2015 Sep;14(5):608-14. doi: 10.1016/j.jcf.2015.03.004. Epub 2015 Mar 26.

Reference Type DERIVED
PMID: 25819269 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/205/205.438_Literature.pdf

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-019802-17

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

205.438

Identifier Type: -

Identifier Source: org_study_id